Kiora Pharmaceuticals, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Kiora is a clinical-stage specialty pharmaceutical company developing ophthalmic therapies. The unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
The principal programs are KIO-301 for degenerative retinal diseases and KIO-104 for posterior non-infectious uveitis. Development of KIO-101 and KIO-201 is paused while the Company seeks partners.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Collaboration revenue | $16.0 million | $0 | +$16.0 million |
| Operating expenses | $2.8 million | $1.9 million | +$0.9 million |
| Operating income (loss) | $13.2 million | $(1.9) million | +$15.1 million |
| Net income (loss) | $13.5 million | $(1.9) million | +$15.3 million |
| Net income (loss) per basic share | $0.52 | $(1.00) | Improved |
| Cash flow from operations | $13.6 million | $(3.1) million | +$16.7 million |
| Cash flow from financing | $15.2 million | $0.5 million | +$14.7 million |
Operating margin was approximately 82.6% and net margin was approximately 84.1%, primarily because the $16.0 million upfront license payment was recognized immediately. These margins are not representative of recurring product economics.
- Cash and cash equivalents were $31.3 million at March 31, 2024, versus $2.5 million at December 31, 2023. Total cash, including restricted cash, was $31.3 million.
- Total assets were $42.4 million and total liabilities were $7.5 million. The Company reported stockholders’ equity of $34.9 million.
- There was no reported conventional debt. Liabilities included $5.1 million of contingent consideration and $0.8 million of deferred tax liabilities.
- The accumulated deficit was $133.5 million, and management stated that losses and negative cash flows are expected to continue.
Material changes versus the prior comparable period
- In January 2024, Kiora licensed exclusive worldwide, ex certain Asian countries, development and commercialization rights for KIO-301 to Théa Open Innovation. The transaction generated a $16.0 million non-refundable upfront payment, recognized as revenue in Q1.
- The agreement also provides eligibility for up to $285 million in clinical, regulatory and commercial milestones, tiered royalties of up to the low-20% range on net sales, and reimbursement of certain KIO-301 research and development expenses. These potential amounts were not included in Q1 revenue.
- Research and development expense increased $1.1 million to $1.5 million, primarily due to a $0.7 million payment to the University of California associated with the TOI transaction and additional KIO-301 activities, partly offset by collaboration reimbursement credits.
- General and administrative expense increased modestly by $27,000 to $1.3 million.
- Financing included approximately $13.8 million of net proceeds from a February private placement and $1.4 million from warrant exercises.
- Common shares outstanding increased from 7.7 million at December 31, 2023 to 26.3 million at March 31, 2024. The Company also had approximately 71.0 million shares issuable upon exercise of outstanding warrants at March 31, 2024.
Outlook, commentary, risks and unusual items
- Management stated that cash on hand is expected to fund planned operations through 2026, although the financial statements state that resources are sufficient for at least 12 months after issuance. The Company expects to require additional financing to continue development.
- KIO-301’s Phase 1b trial completed enrollment and the last patient visit in 2023. Complete data were expected to be presented at the May 2024 ARVO conference. The Company is planning the ABACUS-2 Phase 2 trial in retinitis pigmentosa.
- Kiora is designing a randomized, controlled Phase 2 trial of KIO-104. The Tranche B warrants reference expected topline data from this trial in 2026.
- The Company has no committed external funding source. Future equity or convertible financing could materially dilute shareholders; debt financing could add fixed obligations and restrictive covenants; licensing transactions could require relinquishing valuable rights.
- The $16.0 million Q1 revenue is a non-recurring upfront license payment. Future revenue is expected to fluctuate based on milestone timing, royalties, collaborations and potential product approvals, none of which is assured.
- Contingent consideration had a fair value of $5.1 million at March 31, 2024, against maximum contractual obligations of approximately $18.8 million. The valuation depends on milestone probabilities, timing and discount rates.
- At the May 1, 2024 annual meeting, shareholders approved an increase in authorized common shares to 150 million, a new equity incentive plan and issuance of up to 49.4 million shares upon exercise of the Tranche A and Tranche B warrants.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. No material changes to previously disclosed risk factors were reported, and no legal proceedings were pending as of March 31, 2024.
Most important facts for investors to verify
- Whether KIO-301 clinical data support progression of ABACUS-2 and achievement of the development, regulatory and commercial milestones under the TOI agreement.
- The sustainability of cash resources given projected clinical spending, operating losses and the Company’s stated need for future financing.
- The potential dilution from approximately 71.0 million outstanding warrant shares, including up to 49.4 million Tranche A and B warrant shares and 11.4 million pre-funded warrant shares.
- Whether future milestone, royalty and research reimbursement revenue is recognized and whether sublicense fees or other transaction costs materially offset it.
- The probability and timing of the approximately $5.1 million fair-valued contingent consideration obligations and maximum potential payments of approximately $18.8 million.
- Progress and financing requirements for KIO-104, and whether KIO-101 and KIO-201 remain paused or are successfully partnered.